Behind the Science of Molecular Targeting of Biologics

This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, as well as discusses the interleukin(IL)-17 class of biologics, how this class compares to other classes such as IL-23 and TNFα, and how bimekizumab sets itself apart from other biologics in the pipeline for psoriasis.